Prospective monitoring of adjuvant treatment in high-risk melanoma patients: Lactate dehydrogenase and protein S-100B as indicators of relapse

Melanoma Research

Volumn 19, Issue 1, 2009, Pages 31-35

  Egberts, Friederike ^a   Hitschler, Wolfgang N ^a   Weichenthal, Michael ^a   Hauschild, Axel ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Lactate dehydrogenase; Melanoma; Metastasis; S 100B; Tumor marker

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; DACARBAZINE; LACTATE DEHYDROGENASE; PROTEIN S100B; TUMOR MARKER; VINDESINE;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISTANT METASTASIS; DRUG MONITORING; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IN-TRANSIT METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGIONAL METASTASIS; SKIN METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; L-LACTATE DEHYDROGENASE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROSPECTIVE STUDIES; RECURRENCE; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VINDESINE;

EID: 59549102399     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32831993cc     Document Type: Article

References (27)

1. Balch CM, Soong SJ, Gershenwald JE. Prognostic factors analysis of 17 600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
2. Dummer R, Bösch U, Panizzon R, Bloch PH, Burg G. Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001; 203:75-80.
3. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Kortmann RD, et al. Brief guidelines: malignant melanoma of the skin. JDDG 2006; 4:344-349.
4. Chu TM. Prostate-specific antigen and early detection of prostate cancer. Tumour Biol 1997; 18:123-134.
5. Abraha HD, Fuller LC, Du Vivier AWP, Higgens EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 137:381-385.
6. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, et al. S-100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999; 56:338-344.
7. Martenson ED, Hansson LO, Nilsson B, Schoultz von E, Brahme EM, Ringborg U, et al. Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19:824-831.
8. Von Schoultz E, Hansson LO, Djureen E, Hansson J, Kärnell R, Nilsson B, et al. Prognostic value of serum analyses of S-100B protein in malignant melanoma. Melanoma Res 1996; 6:133-137.
9. Schute ES, Diepken TL, von den Driesch P. Clinical and prognostic relevance of serum S-100B protein in malignant melanoma. Br J Dermatol 1998; 138:426-430.
10. Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 1998; 77:2210-2214.
11. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Gläser R, Henze E, et al. Prognostic significance of serum S-100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999; 9:155-161.
12. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, et al. Predictive value of serum S-100B for monitoring patients with melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999; 140:1065-1071.
13. Jury CS, Mc Allister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000; 143:269-274.
14. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
15. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, et al. S-100 beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17:1891-1896.
16. Huang CL, Provost N, Ashfag AA, Kopf AW, Levin L, Bart R. Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol 1998; 39:451-463.
17. Weiss M, Loprinzi C, Creagan E, Dalton J, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. J Am Med Assoc 1995; 274:1703-1705.
18. Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol 2000; 143:256-268.
19. Djukanovic D, Hofmann U, Sucker A, Schadendorf D. Melanoma tumour markers S-100B and MIA: evaluation of stability in serum and blood upon storage and processing. Br J Dermatol 2001; 145:1030-1031.
20. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology 2006; 213:187-191.
21. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S-100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003; 13:45-49.
22. Krähn G, Kaskel P, Sander S, Pereira J, Waizenhöfer Y, Wortmann S, et al. S-100B is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001; 21: 1311-1316.
23. Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 2000; 20:5059-5064.
24. Schlangenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Schwartz M, et al. Significance of serum S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence. Melanoma Res 2000; 10:451-419.
25. Domingo-Domenech J, Molina R, Castel T, Montagut C, Puig S, Conill C, et al. Serum protein S100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon-comparison with tyrosinase RT-PCR. Oncology 2005; 68:341-349.
26. Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, et al. Prognostic implications of protein S-100 beta serum levels in the clinical outcome of high-risk melanoma patients. Tumor Biol 2007; 28:264-272.
27. Gamier JP, Letellier S, Cassinat B, Lebbe C, Kerob D, Baccard M, et al. Clinical value of combined determination of plasma L-DOPA/tyrosinase ratio, S-100B, MIA and LDH in melanoma. Eur J Cancer 2007; 43:816-821.